J&J seeks to fend off competition with CARTITUDE-4 data

New data from Johnson & Johnson's (NYSE: JNJ) Phase III CARTITUDE-4 study highlight the performance of Carvykti (ciltacabtagene autoleucel) in multiple myeloma.

Presented during the ongoing American Society of Hematology (ASH) meeting, the results show extended survival outcomes and high rates of minimal residual disease (MRD). People in the trial had relapsed or refractory disease.

The trial showed that 89% of patients evaluable for MRD assessment achieved MRD negativity with Carvykti, compared to 38% in the standard therapy arm. At a follow-up of nearly three years, progression-free survival and overall survival rates were significantly higher in patients treated earlier in their disease course.